-
Something wrong with this record ?
7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties
L. Gorecki, D. Muthna, S. Merdita, M. Andrs, T. Kucera, R. Havelek, L. Muckova, T. Kobrlova, J. Soukup, P. Krupa, L. Prchal, O. Soukup, J. Roh, M. Rezacova, J. Korabecny
Language English Country France
Document type Journal Article
- MeSH
- Ataxia Telangiectasia Mutated Proteins MeSH
- Cisplatin pharmacology MeSH
- Indoles MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Antineoplastic Agents * pharmacology MeSH
- Pyrazoles pharmacology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Chemoresistance of cancer cells is a hallmark of treatment failure and the poor patient prognosis. The mechanism of resistance is often connected to the overexpression of specific kinases involved in DNA damage response cascade. Contrary, selected kinase inhibition can augment cancer cell sensitization to conventional therapy, enabling more efficient treatment. Among those kinases, ataxia-telangiectasia and Rad3-related kinase (ATR), the major responder to replication stress, stands out as one of the most attractive targets. Inspired by clinical candidates targeting ATR, we designed and prepared a small, focused library of 40 novel compounds building on 7-azaindoles, 2,7-diazaindoles, and 1H-pyrazoles as core structures. All the compounds alone or combined with cisplatin (CDDP) were screened against a panel of nine cancer cell lines and one healthy cell line. Three highlighted compounds (3, 22, and 29) were selected for broad oncology panel screening containing 104 kinases. Only compound 29, the 2,7-diazaindole representative, showed ATR inhibitory efficacy with the IC50 around 10 μM. In contrast, the compound 22, 7-azaindole congener with the most pronounced cytotoxicity profile exceeding CDDP alone or in combination with CDDP, expressed the multi-kinase activity. Highlighted representatives, including compound 29, were also effective alone against primary glioblastoma. Overall, we showed that 7-azaindole, and 2,7-diazaindole scaffolds could be considered novel pharmacophores delivering anticancer activity.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024217
- 003
- CZ-PrNML
- 005
- 20250513151800.0
- 007
- ta
- 008
- 221017e20220630fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2022.114580 $2 doi
- 035 __
- $a (PubMed)35793579
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Gorecki, Lukas $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 245 10
- $a 7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties / $c L. Gorecki, D. Muthna, S. Merdita, M. Andrs, T. Kucera, R. Havelek, L. Muckova, T. Kobrlova, J. Soukup, P. Krupa, L. Prchal, O. Soukup, J. Roh, M. Rezacova, J. Korabecny
- 520 9_
- $a Chemoresistance of cancer cells is a hallmark of treatment failure and the poor patient prognosis. The mechanism of resistance is often connected to the overexpression of specific kinases involved in DNA damage response cascade. Contrary, selected kinase inhibition can augment cancer cell sensitization to conventional therapy, enabling more efficient treatment. Among those kinases, ataxia-telangiectasia and Rad3-related kinase (ATR), the major responder to replication stress, stands out as one of the most attractive targets. Inspired by clinical candidates targeting ATR, we designed and prepared a small, focused library of 40 novel compounds building on 7-azaindoles, 2,7-diazaindoles, and 1H-pyrazoles as core structures. All the compounds alone or combined with cisplatin (CDDP) were screened against a panel of nine cancer cell lines and one healthy cell line. Three highlighted compounds (3, 22, and 29) were selected for broad oncology panel screening containing 104 kinases. Only compound 29, the 2,7-diazaindole representative, showed ATR inhibitory efficacy with the IC50 around 10 μM. In contrast, the compound 22, 7-azaindole congener with the most pronounced cytotoxicity profile exceeding CDDP alone or in combination with CDDP, expressed the multi-kinase activity. Highlighted representatives, including compound 29, were also effective alone against primary glioblastoma. Overall, we showed that 7-azaindole, and 2,7-diazaindole scaffolds could be considered novel pharmacophores delivering anticancer activity.
- 650 12
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a ATM protein $7 D064007
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cisplatina $x farmakologie $7 D002945
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indoly $7 D007211
- 650 _2
- $a pyrazoly $x farmakologie $7 D011720
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Muthna, Darina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03, Hradec Kralove, Czech Republic
- 700 1_
- $a Merdita, Sara, $d 1999- $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Faculty of Pharmacy in Hradec Kralové, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic $7 xx0331992
- 700 1_
- $a Andrs, Martin $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic; Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, Prague 4, 142 00, Czech Republic
- 700 1_
- $a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03, Hradec Kralove, Czech Republic
- 700 1_
- $a Muckova, Lubica $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Kobrlová, Tereza, $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic $d 1991- $7 xx0277928
- 700 1_
- $a Soukup, Jiri $u The Fingerland Department of Pathology, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Krupa, Petr $u Department of Neurosurgery, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Prchal, Lukas $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Roh, Jaroslav $u Faculty of Pharmacy in Hradec Kralové, Charles University, Akademika Heyrovskeho 1203, 500 05, Hradec Kralove, Czech Republic
- 700 1_
- $a Rezacova, Martina $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, Simkova 870, 500 03, Hradec Kralove, Czech Republic. Electronic address: rezacovam@lfhk.cuni.cz
- 700 1_
- $a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05, Hradec Kralove, Czech Republic. Electronic address: jan.korabecny@fnhk.cz
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 240 (20220630), s. 114580
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35793579 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20250513151802 $b ABA008
- 999 __
- $a ok $b bmc $g 1854118 $s 1175507
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 240 $c - $d 114580 $e 20220630 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20221017
